Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Subscribe to Pharma in Focus

Sign Up Now

Pharma in Focus is considered essential daily reading in the Australian and NZ pharma industry.

In production for 14 years, it is emailed twice daily to more than 11,000 pharma industry professionals throughout Australia and NZ.

For just $454.50 a year (plus GST) Pharma in Focus puts you ahead of the game by delivering:

  • Key Aussie & NZ pharma news every working day
  • Daily in-depth features covering all aspects of pharma from drug approvals to employment issues
  • Full coverage and analysis of PBAC, PBS and TGA decisions
  • Ten survey-based white papers per year (total value $1500)

New to Pharma in Focus? Sign up below for your FREE two week trial.

Time to subscribe? Sign up below for your 12 month subscription.

Need multiple licenses? We have great corporate rates. Contact our friendly subscription managers on 02 9939 1881 or admin@pharmainfocus.com.au for our latest prices.

3 Simple Steps

1 Fill in your details below and submit

2 Make your subscription choice

3 Make your payment choice (Credit Card, Direct Deposit or Cheque)

Approvals Action
Pfizer antibiotic sees first generic
Southern Cross has added the first copy of a Pfizer antibiotic to the ARTG in a week which saw a flurry of generic activity.
Pipeline Monitor
Lilly, Amgen rev up major drugs
Lilly's Taltz and Amgen's Repatha both won significant extensions from the FDA this week as the companies attempt to build blockbuster futures out of their pipelines.
Perspective
Big city moves not just about the view
Moves by pharma companies to leave suburban sites for slick new city offices is as much about how they want to be seen as it is about the scenery.